Pen-Rx Project

Raising $3M for FDA Pre-IND Meeting for accelerated approval of patented compounded transdermal alternative to opioids.

Facebook Twitter LinkedIn

Pen-Rx has a patented compounded prescriptive transdermal emulsion 10% Gabapentin-5% Naproxen as an alternative to opioids for the treatment of peripheral pain whose successful treatment of several hundred patients suffering from moderate to severe peripheral pain was recently published in the Journal of Drug Research and Development. We are looking for $3M in an equity investment so that the combination drug can be presented to the FDA on a pre-IND basis for accelerated approval within the next 6 months.

Ready to Ask For Funding for your company?

Post a Funding Request

Pen-Rx Project is no longer seeking funding.